Brown BM - Search Results

1

Structural Determinants for the Selectivity of the Positive KCa3.1 Gating Modulator 5-Methylnaphtho[2,1-d]oxazol-2-amine (SKA-121).

Brown BM, Shim H, Zhang M, Yarov-Yarovoy V, Wulff H. Brown BM, et al. Mol Pharmacol. 2017 Oct;92(4):469-480. doi: 10.1124/mol.117.109421. Epub 2017 Jul 31. Mol Pharmacol. 2017. PMID: 28760780 Free PMC article.

2

New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1.

Coleman N, Brown BM, Oliván-Viguera A, Singh V, Olmstead MM, Valero MS, Köhler R, Wulff H. Coleman N, et al. Among authors: brown bm. Mol Pharmacol. 2014 Sep;86(3):342-57. doi: 10.1124/mol.114.093286. Epub 2014 Jun 23. Mol Pharmacol. 2014. PMID: 24958817 Free PMC article.

3

A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo.

Oliván-Viguera A, Valero MS, Coleman N, Brown BM, Laría C, Murillo MD, Gálvez JA, Díaz-de-Villegas MD, Wulff H, Badorrey R, Köhler R. Oliván-Viguera A, et al. Among authors: brown bm. Mol Pharmacol. 2015 Feb;87(2):338-48. doi: 10.1124/mol.114.095745. Epub 2014 Dec 2. Mol Pharmacol. 2015. PMID: 25468883 Free PMC article.

4

KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma.

Brown BM, Pressley B, Wulff H. Brown BM, et al. Curr Neuropharmacol. 2018;16(5):618-626. doi: 10.2174/1570159X15666170630164226. Curr Neuropharmacol. 2018. PMID: 28676010 Free PMC article.

5

Pharmacology of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels.

Brown BM, Shim H, Christophersen P, Wulff H. Brown BM, et al. Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:219-240. doi: 10.1146/annurev-pharmtox-010919-023420. Epub 2019 Jul 23. Annu Rev Pharmacol Toxicol. 2020. PMID: 31337271 Free PMC article. Review.

6

The Trials and Tribulations of Structure Assisted Design of K_Ca Channel Activators.

Shim H, Brown BM, Singh L, Singh V, Fettinger JC, Yarov-Yarovoy V, Wulff H. Shim H, et al. Among authors: brown bm. Front Pharmacol. 2019 Sep 20;10:972. doi: 10.3389/fphar.2019.00972. eCollection 2019. Front Pharmacol. 2019. PMID: 31616290 Free PMC article.

7

Development of a QPatch automated electrophysiology assay for identifying KCa3.1 inhibitors and activators.

Jenkins DP, Yu W, Brown BM, Løjkner LD, Wulff H. Jenkins DP, et al. Among authors: brown bm. Assay Drug Dev Technol. 2013 Nov-Dec;11(9-10):551-60. doi: 10.1089/adt.2013.543. Assay Drug Dev Technol. 2013. PMID: 24351043 Free PMC article.

8

Are there superagonists for calcium-activated potassium channels?

Brown BM, Shim H, Wulff H. Brown BM, et al. Channels (Austin). 2017 Nov 2;11(6):504-506. doi: 10.1080/19336950.2017.1376971. Epub 2017 Oct 5. Channels (Austin). 2017. PMID: 28876978 Free PMC article. No abstract available.

9

Recent advances in our understanding of the structure and function of more unusual cation channels.

Brown BM, Nguyen HM, Wulff H. Brown BM, et al. F1000Res. 2019 Jan 30;8:F1000 Faculty Rev-123. doi: 10.12688/f1000research.17163.1. eCollection 2019. F1000Res. 2019. PMID: 30755796 Free PMC article. Review.

10

The riluzole derivative 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a mixed KCa2 activator and NaV blocker, is a potent novel anticonvulsant.

Coleman N, Nguyen HM, Cao Z, Brown BM, Jenkins DP, Zolkowska D, Chen YJ, Tanaka BS, Goldin AL, Rogawski MA, Pessah IN, Wulff H. Coleman N, et al. Among authors: brown bm. Neurotherapeutics. 2015 Jan;12(1):234-49. doi: 10.1007/s13311-014-0305-y. Neurotherapeutics. 2015. PMID: 25256961 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

155 results

Search Page

Filters